Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Teladoc Health (TDOC)
Teladoc Health reported Q2 2026 revenue of $606.9 million against consensus estimates of $615 million to $628 million -- and the stock fell almost 30% in a single session. Levi & Korsinsky is investigating on behalf of TDOC investors who lost money
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- A revenue shortfall of up to $21 million against Wall Street estimates wiped out roughly a quarter of Teladoc Health's (NYSE: TDOC) market value, with shares dropping around 29% intraday after the Company posted Q2 2026 consolidated revenue of $606.9 million. If you lost money on TDOC shares, you are encouraged to click here to submit your losses for review. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Consensus estimates going into the print ranged from $615 million to $628 million. Reported revenue came in at $606.9 million -- down approximately 4% year-over-year and below the low end of the analyst range, alongside BetterHelp segment revenue of only $212.6 million, down 12%. year-over-year. GAAP EPS of -$0.21 beat the -$0.25 consensus, but the top-line miss drove the selloff.
Alongside the miss, Teladoc reduced its full-year 2026 revenue outlook to $2.36 billion to $2.45 billion and slashed BetterHelp segment revenue growth expectations to decline 19% to 12.7%.
Shareholders who purchased TDOC and suffered a loss on the earnings miss may request a no-cost review of their recovery options, or call (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the TDOC Investigation
Q: How much did TDOC stock drop? A: Shares fell nearly 30% after the Company reported Q2 2026 consolidated revenue of $606.9 million, below consensus expectations, and cut its full-year guidance. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: What is the TDOC investigation about? A: A securities investigation is pending concerning Teladoc Health (NYSE: TDOC) regarding potentially materially false or misleading statements about the Company's forward revenue outlook. Shares were falling nearly 30% following Teladoc’s full-year 2026 revenue guidance cut.
Q: Who is eligible to participate in the TDOC investigation? A: Investors who purchased TDOC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do TDOC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my TDOC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TDOC and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations are generally handled on a contingency basis -- no upfront fees, no retainer, and no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
